Clinical trial • Phase III • Psychiatry
NTX-1955 for Generalized anxiety disorder
Phase III trial of NTX-1955 for Generalized anxiety disorder. 60 participants.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Generalized anxiety disorder
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 23-06-2025
- First CTIS Authorization Date
- 06-08-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 60
Eligibility
Recruits 60 No vulnerable populations selected (isVulnerablePopulationSelected:false). Consent/assent handling not described..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected:false). Consent/assent handling not described.
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 14
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 60
Netherlands
- Earliest CTIS Part Ii Submission Date
- 23-07-2025
- Latest Decision Or Authorization Date
- 25-09-2025
- Processing Time Days
- 64
- Number Of Sites
- 1
- Number Of Participants
- 60
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Psychiatry
- Contact Person Name
- Gabriel Jacobs
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Newleos Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- NTX-1955
- Routes Of Administration
- oral
- Route
- oral
Related trials
Other published trials that may interest you.